Search This Blog

Wednesday, October 31, 2018

Amgen price target lowered to $182 from $193 at RBC Capital


RBC Capital analyst Kennen MacKay lowered his price target on Amgen to $182 and kept his Sector Perform rating after its Q3 results. The analyst says the quarter was “in line” with “safe” expectations, even as the company’s core business competition is “slow” to impact sales. MacKay further cites an “astonishing” launch of Aimovig with 100K new patients, but also notes the sales decline against sequential volume growth for Amgen’s Repatha.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.